The face has fat compartments — and they don't all go at the same time

Your face is not a uniform layer of tissue. It has distinct fat compartments arranged in deep and superficial layers — the buccal fat pad, the malar fat, the nasolabial compartments, the temples. These compartments maintain the structural fullness that reads as youth. When you lose weight rapidly, these pads deflate unevenly, and the face you're left with may look gaunt, hollowed around the temples, or sharper in a way that adds apparent age.

This happens with any rapid weight loss — crash dieting, illness, any intervention that takes weight off faster than the skin can adapt. GLP-1 drugs are associated with it at higher rates partly because the weight loss can be so rapid. The drug itself isn't aging your face. The speed of change is.

15–20%
Average body weight reduction in STEP trials for semaglutide — a rate of loss that can outpace the skin's ability to adapt, particularly in women over 40 with already-declining collagen
2023
Year GLP-1 receptors were confirmed in human keratinocytes — meaning semaglutide may have direct effects on skin cell function beyond what weight change alone would produce
1.2–1.6g
Per kg of body weight — protein intake range used in research protocols to help preserve lean mass and skin integrity during significant weight loss on GLP-1 medications

Why the skin doesn't snap back — and why age matters

Skin elasticity depends on two proteins: collagen (structural strength) and elastin (the recoil mechanism). Both decline with age. In your 20s, skin adapts to body composition changes quickly. In your 40s and beyond, that adaptability is significantly reduced. Rapid fat loss leaves behind a collagen-elastin network that was sized for more volume — and it doesn't automatically tighten to fit the new contours.

This is why dermatologists report seeing "Ozempic face" more commonly in patients who are older and who have lost weight quickly. Slower weight loss — even with the same total loss — gives skin more time to remodel. The GLP-1 drugs are so effective that the speed can be difficult to moderate without intentional plate-by-plate effort.

Research note

A 2023 paper in the Journal of the European Academy of Dermatology and Venereology confirmed the presence of GLP-1 receptors in human keratinocytes and dermal fibroblasts, suggesting semaglutide may directly influence skin cell turnover and wound healing — independently of weight loss. Separately, a Penn Medicine analysis found that patients on semaglutide who maintained adequate protein intake showed meaningfully better preservation of lean body mass compared to those who did not — with downstream implications for skin and muscle quality.

What actually helps — and what doesn't

The cosmetic industry's response to "Ozempic face" has been aggressive: fillers, radiofrequency tightening, and biostimulators like Sculptra are all being marketed specifically to GLP-1 users. Some of this is genuinely useful. A lot of it is opportunistic.

Protein intake is the most evidence-grounded modifiable factor. GLP-1 medications suppress appetite substantially, and many users are eating far less protein than they need to preserve lean mass. In the absence of adequate protein, the body catabolizes muscle as well as fat — making body composition worse, not just smaller, and contributing to the gaunt appearance. Prioritizing protein at every meal matters on these medications.

For skin specifically, building a routine around actives that support collagen synthesis — retinoids, vitamin C, and niacinamide — gives the skin's structural proteins the best chance to respond to volume changes. Radiofrequency devices (both in-clinic and medical-grade at-home versions) have reasonable evidence for stimulating collagen in lax skin, with the caveat that results are modest compared to filler.

Filler in recently-deflated facial fat compartments works well for most people. The caution: using too much filler to compensate for volume loss that may still be changing gives unpredictable results. Most experienced injectors now recommend waiting for weight to stabilize before significant filler investment.

Practical note on timing

If you're on a GLP-1 medication and concerned about facial changes, focus on protein intake and topical actives first. Wait until your weight has been stable for at least three months before significant aesthetic investment — the face continues to change as body composition shifts, and treatments done during active weight loss may look different at maintenance weight.

🩺

When to loop in your prescriber

If you're experiencing significant muscle loss alongside fat loss on a GLP-1 medication, discuss protein targets and whether strength training is appropriate for your situation. For significant skin laxity beyond cosmetic concern (such as abdominal skin that's functionally limiting), mention it — some cases qualify for surgical intervention covered by insurance when it meets functional criteria.

Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
  2. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism. 2022;57:101351. doi:10.1016/j.molmet.2021.101351
  3. Wewer Albrechtsen NJ, et al. The biology of glucagon and the consequences of hyperglucagonemia. Biomarkers in Medicine. 2016;10(11):1141–1151. doi:10.2217/bmm-2016-0090
  4. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945